Header Logo

Connection

Marta Batus to Humans

Back to Details
This is a "connection" page, showing publications Marta Batus has written about Humans.
Marta Batus
Connection Strength
0.353
Humans
  1. Pulmonary metastasectomy in bone and soft tissue sarcoma with metastasis to the lung. Interact Cardiovasc Thorac Surg. 2021 11 22; 33(6):879-884.
    View in: PubMed
    Score: 0.045
  2. The clinical utility of next-generation sequencing for bone and soft tissue sarcoma. Acta Oncol. 2022 Jan; 61(1):38-44.
    View in: PubMed
    Score: 0.045
  3. Marta Batus on the New Direct-to-Consumer Advertising for Nivolumab, and Its Impact on Oncology Practice. Oncology (Williston Park). 2016 Jun; 30(6):506, 523.
    View in: PubMed
    Score: 0.031
  4. Future directions for pediatric and young adult bone sarcoma. Curr Probl Cancer. 2013 Jul-Aug; 37(4):225-35.
    View in: PubMed
    Score: 0.025
  5. Optimal management of metastatic melanoma: current strategies and future directions. Am J Clin Dermatol. 2013 Jun; 14(3):179-94.
    View in: PubMed
    Score: 0.025
  6. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Rev Anticancer Ther. 2010 Oct; 10(10):1589-99.
    View in: PubMed
    Score: 0.021
  7. Association between neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and survival in undifferentiated pleomorphic sarcoma (NLR, PLR, and overall survival in UPS). Surg Oncol. 2023 Aug; 49:101949.
    View in: PubMed
    Score: 0.012
  8. Does synovial sarcoma grade predict oncologic outcomes, and does a low-grade variant exist? J Surg Oncol. 2022 Jun; 125(8):1301-1311.
    View in: PubMed
    Score: 0.011
  9. PET-CT staging affects time to treatment in sarcoma. Surg Oncol. 2022 May; 41:101732.
    View in: PubMed
    Score: 0.011
  10. What is the clinical impact of staging and surveillance PET-CT scan findings in patients with bone and soft tissue sarcoma? J Surg Oncol. 2022 Apr; 125(5):901-906.
    View in: PubMed
    Score: 0.011
  11. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition. J Immunol Methods. 2021 03; 490:112956.
    View in: PubMed
    Score: 0.011
  12. Neoadjuvant Interdigitated Chemoradiotherapy Using Mesna, Doxorubicin, and Ifosfamide for Large, High-grade, Soft Tissue Sarcomas of the Extremity: Improved Efficacy and Reduced Toxicity. Am J Clin Oncol. 2019 01; 42(1):1-5.
    View in: PubMed
    Score: 0.009
  13. The serum-based VeriStrat? test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer. 2018 03 20; 18(1):310.
    View in: PubMed
    Score: 0.009
  14. Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer. BMC Cancer. 2017 02 16; 17(1):141.
    View in: PubMed
    Score: 0.008
  15. Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience. Pediatr Blood Cancer. 2017 04; 64(4).
    View in: PubMed
    Score: 0.008
  16. Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer. Am J Clin Oncol. 2015 Dec; 38(6):605-9.
    View in: PubMed
    Score: 0.007
  17. Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response. J Thorac Oncol. 2015 Oct; 10(10):1475-80.
    View in: PubMed
    Score: 0.007
  18. Survival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale. Am J Hosp Palliat Care. 2016 May; 33(4):374-80.
    View in: PubMed
    Score: 0.007
  19. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy. Pract Radiat Oncol. 2014 Sep-Oct; 4(5):342-348.
    View in: PubMed
    Score: 0.007
  20. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2013 Jul; 14(4):370-5.
    View in: PubMed
    Score: 0.006
  21. Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Anticancer Res. 2012 May; 32(5):1705-10.
    View in: PubMed
    Score: 0.006
  22. PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy. Br J Cancer. 2011 Dec 06; 105(12):1920-6.
    View in: PubMed
    Score: 0.006
  23. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol. 2011 Jun; 6(6):1079-86.
    View in: PubMed
    Score: 0.005
  24. Neoadjuvant treatment of rectal gastrointestinal stromal tumors with imatinib. Am Surg. 2010 Aug; 76(8):E110-2.
    View in: PubMed
    Score: 0.005
  25. Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer. Lung Cancer. 2011 Feb; 71(2):186-90.
    View in: PubMed
    Score: 0.005
  26. Idiopathic hemophagocytic syndrome with a fulminant clinical course. Clin Adv Hematol Oncol. 2008 Aug; 6(8):587-90.
    View in: PubMed
    Score: 0.004
  27. Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer. Genes Chromosomes Cancer. 2007 Apr; 46(4):397-405.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.